Activation of the tyrosine kinase of the c-src gene product, pp60c-src, has been shown to occur in nearly every primary colorectal carcinoma, and is found as early as in polyps of high malignant potential. However, no studies have addressed potential pp60c-src changes which occur during progression. To examine this question, we have studied kinase activity and protein levels in 7 colonic polyps, 19 primary lesions, and 19 liver metastases relative to normal colonic mucosa. Significant increases in tyrosine kinase activity were seen as early as in colonic polyps of high malignant potential. Further increases were observed in activity and level in primary tumors. However, the greatest increases in activity and protein levels were observed in liver metastases. Additionally, six metastatic lesions were obtained in which synchronous primary tumor was resected. In each of these liver metastases, pp60c-src activity and level were significantly increased relative to the corresponding primary tumor, as well as to normal colonic mucosa. Our results demonstrate that progression of colon primary tumors to liver metastases correlates with increased pp60c-src kinase activity and protein level.
and occurs at an early stage of tumor development ( 15 ) . Activation of the tyrosine kinase of the c-src gene product, pp6Oc-src has also been demonstrated to occur at an early stage of tumor development, specifically, in polyps of high malignant potential but not in small benign polyps ( 17) . Strikingly, most, if not all primary colon carcinomas and the cell lines established from them, have demonstrated activation of the pp6011sC tyrosine kinase ( 18, 19) .
The mechanism ofpp60c-src activation in colon carcinomas remains unknown, as does its potential role in tumor development and progression. However, recent studies have demonstrated that specific inhibitors of tyrosine kinases, such as herbimycin A (20) , growth inhibit every colon tumor cell line with activated pp60c-src and that the extent ofgrowth inhibition correlates closely with decreased pp60-src activity (21) . Additionally, while the role of pp60csrc regulation in growth and differentiation of normal colon cells remains to be understood, many studies have implicated its regulation as important to several cellular processes, including regulation of mitosis (22) (23) (24) , response to growth factor-mediated cellular proliferation (25, 26) , and differentiation of several mature cell types (27, 28) . Furthermore, because increased pp60>src tyrosine kinase activity is associated with malignant transformation, reviewed by Hunter (29), regulation of level and/or activity may be critical in growth regulation and malignant transformation of colonic epithelial cells. No studies have addressed potential pp60>src changes that occur during progression of colorectal carcinoma to metastatic disease. Whether or not further alterations in pp6oCsrc activity and/or level are required for the transformed cell to gain full metastatic potential is unknown. To examine this question, we have studied tyrosine kinase activity and protein levels ofpp60>src in fresh tissues from a representative number oflesions comprising the spectrum ofbenign colon polyps to metastatic colorectal liver disease. Additionally, several synchronous primary and metastatic lesions from the same patient were examined to determine if Analysis ofdata. Relative pp60cs7c in vitro protein kinase activity was determined by densitometric scanning of the 60-kD band, representing autophosphorylation, and the 44-kD band, representing enolase phosphorylation, on the resulting autoradiographs. The level of pp6Oc-src protein in individual tumors was determined by densitometric scanning of the 60-kD band on autoradiographs of the immunoblots. Densitometry was done using a DU-7 spectrophotometer (Beckman Instruments, Inc., Fullerton, CA), and results were expressed as relative changes compared to normal colonic mucosa. Changes in activity and level of polyps and primary tumors are expressed as the n-fold increase relative to normal colonic mucosa from the same patient for all samples. Data for liver me- The clinical samples were characterized according to the location, histologic differentiation, Dukes' stage ofthe primary tumor, and patient age. The statistical significance ofthe differences in activity and level of pp60csrc between normal colonic mucosa and tumors was analyzed using the Wilcoxon signedrank test. Thus, the value of pp6Oesrc activity and level in the presence of the other available prognostic factors was determined directly. All computations were done with the StatWorks program (Cricket Software, Philadelphia, PA).
Results
Activity and level of pp60csrc in colonic polyps. To examine potential changes that can occur during progression to metastasis, we determined kinase activity and levels ofpp6O'src relative to adjacent normal mucosa in a representative number of lesions comprising the spectrum ofbenign colon polyps to metastatic colorectal liver disease. Additionally, several primary colon tumors and synchronous metastases to the liver were examined. Histologic examination of specimens demonstrated that the normal tissue section contained primarily normal colonic mucosa, where as polyp and primary tumor sections consisted of the superficial components of the hyperproliferative polyp or invasive adenocarcinoma, respectively. The results for colonic polyps are summarized in Table I . Relative kinase activities and levels of pp6Ocsrc were determined as described in Methods. When small polyps were examined, no increase was observed in autophosphorylation or enolase phosphorylation. In contrast, substantial increases in kinase activity were observed in two large (> 2 cm) benign villous adenomas. No sig- The pp6Oc-src levels in primary carcinomas ranged from 1.1 to 3.1 times that of adjacent normal mucosa and on an average were 2.4-fold higher than in normal tissues. Examples of activity and level of pp6Ocsrc in primary tumors are seen in Fig. 2 . Specimens from tumors and adjacent normal mucosae were obtained and processed as described in Fig. 1 ( 13 patients) and a second group undergoing liver biopsy or resection at the time ofprimary tumor resection (6 patients). None had received any biologic therapy or chemotherapy within 6 mo before surgery. Total kinase activity and pp6Oc-src levels for individual metastatic lesions were compared to the corresponding normal mucosa from the same patient when available, and unpaired liver metastases were compared to the average activity or level of a randomized pool of normal mucosal samples. The pp6oCsrc activities and levels in normal hepatic parenchyma were also determined. The values were always lower than observed in normal colonic mucosa (data not shown). As shown in Table III , the greatest changes in kinase activity and protein level were consistently seen in the liver metastases. The kinase activity of metastatic lesions ranged from 4.6 to 390 times the activity in normal mucosa and on average were 90-fold higher when measured by auto-phosphorylation and 41-fold higher when measured by enolase phosphorylation (Table III) . There appeared to be no differences in pp6oc.src activity based on age or sex of the patient or Dukes' stage at the time of initial presentation.
The levels of pp6O`csrc were also consistently increased in liver metastases. Protein levels ranged from 1.0 to 1 1.1 and were elevated an average of fivefold in liver metastases relative to normal mucosa. Calculation of specific activity revealed further increases of pp6c-src activity in metastatic disease. Thus, both specific activity and level of pp6O-src are significantly increased in liver metastases relative to primary tumors, resulting in highly elevated total pp6O.src kinase activity.
The results ofpp60c-src activity and levels in all tissues examined are summarized in Table IV and Fig. 3 . Increases in pp6Oc-src kinase activity were seen as early as in colonic polyps, and increases in both pp6oC-SrC activity and level were observed in primary tumors. However, the highest pp6Oc-src activities and levels were consistently observed in liver metastases, as described above. Fig. 3 A demonstrates that with progression to metastatic disease there is a progressive increase in pp6oc-src levels; however, the marked changes in total kinase activity and specific activity seen in the metastases cannot be solely accounted for by changes in the amount or levels of protein. The results of the kinase assays were also analyzed relative to the size of the polyps and the Dukes' stage of the primary tumors, as shown in Fig. 3 B) . Polyps with greater malignant potential based on size > 2 cm were found to have higher kinase activity than smaller polyps. There were no significant differences in the activity ofthe primary tumors based on the Dukes' stage of the patient at the time of initial presentation. Although statistically significant increases in activity and level were observed in liver metastases, considerable differences among individual patients were apparent. As shown in Fig. 3 B, some metastatic lesions had lower activity than did some primary tumors.
Activity and level of pp6Ocsrc in synchronous lesions. Although the above results demonstrate that both pp6Ocsrc activity and level are increased in many liver metastases relative to primary tumors; the relationship between these increases and progression of the disease cannot be inferred by comparison of sporadic tumors. For analysis of changes during progression, synchronous lesions representing various stages of the disease were examined. Six patients with both primary and metastatic tumors obtained at the same surgery were studied. Immune complex kinase assays and immunoblots of two such patients 5, 8, and 11 ) and the liver metastases (lanes 3, 6, 9, and 12) were observed for both kinase activity and protein level. The results of this subset of patients are summarized in Table V . In every instance, both specific activity and protein level are increased in liver metastases relative to primary tumor. Thus in a given patient, progressive stages of the disease directly correlate with increased pp6oc-src activity and level. Colorectal tumorigenesis is a complex, multistep process, frequently involving the deletion of tumor suppressor genes and the activation of dominant oncogenes. These changes are important events leading to unregulated growth of colon cells; however, acquisition of these malignant characteristics does not necessarily confer the ability to successfully establish distant metastases. Previous studies (33, 34) have shown that the process of metastasis consists of sequentially linked steps involving multiple host-tumor interactions (reviewed by Nicolson [351). Tumor cell heterogeneity leads to generation of a subpopulation of cells with differences in metastatic potential (36) . Therefore, tumor cells acquire the "metastatic phenotype" through additional genetic and epigenetic alterations in primary tumor cells (37, 38).
The genes involved in development of metastatic capacity are poorly understood. Certain genes, such as nm 23 (39) , may function as potential metastasis suppressor genes (reviewed by Liotta et al. [40 ] ). Transfection experiments with some of the known oncogenes such as ras, src, and myc have demonstrated the ability to induce metastatic competency in restricted recipient cells (41) . These results suggest that specific changes do occur after acquisition of the tumorigenic phenotype. However, as yet, little is known about the changes that occur during colon tumor cell progression.
Recent studies by Bolen et al. ( 18) and Cartwright et al. (17, 19) have demonstrated activation of the c-src gene product, pp6O-src, in human colon carcinogenesis, with activation in colonic polyps correlating with malignant potential ( 17) . imens of normal mucosa, primary tumor, and liver metastasis (met) were obtained from the same patient at the same surgery, and processed as described in Fig. 1 ( 19) . Thus, increased pp60`src activity in primary tumors is due mostly to increases in specific activity of the enzyme. Increases in activity appeared independent of age or sex ofthe patient, tumor location, or Dukes' classification of the primary tumors.
The focus of this work was to study the role of pp60C`sc in progression of colorectal cancer. For these studies, liver metastases, the most frequent site of colorectal cancer metastasis, were studied. In every liver metastasis examined, there was a significant increase in pp6Ocsrc activity and level relative to normal colonic mucosa. Increases in metastases were due to both increases in specific activity and levels ofthe protein. As a result (Fig. 4) , the majority of liver metastases have considerably higher pp6Ocsrc activity than that observed in primary tumors. The marked changes in kinase activity seen in liver metastases (Fig. 3) That the changes are indeed reflective oftumor progression was demonstrated in synchronous lesions, i.e., primary and metastatic lesions removed from the same patient at the same surgery. In six ofsix patients in which primary and liver metastases were studied, both pp6Osrc activity and level were significantly higher in the metastases than in the primary tumors. Several technical difficulties inherent in working with tumor specimens might have contributed to the changes in pp60-src level and activity observed among the primary tumors and hepatic metastases, including the amount of stromal infiltration and necrotic tissue present in the samples. Indeed, differences were observed in the amount of viable tumor cells estimated from hematoxylin and eosin-stained sections ofthe tumor specimens analyzed for pp60Csrc. These differences are likely to account, at least in part, for the variation among individual tumors in relative increases in pp6O'src autophosphorylation activities for example, as shown in Fig. 3 B. However, no significant increases or decreases in the estimated percentage of viable tumor cells were noted between primary tumors and hepatic metastases as a group. These results suggest that pp6Ocsrc changes correlate specifically with progression.
No studies have yet addressed a potential role for changes in pp60Ocsrc activity or level as possible contributors to the acquisition ofthe metastatic phenotype in human colon cancer. There is, however, evidence to suggest that phosphorylation ofphysiologic substrates for protein tyrosine kinases may be important for production of metastases in some tumor cells (reviewed by Bishop [43] ). Tyrosine kinase substrates such as the integrins, talin, and viniculin are components of cell adhesion plaques. One possible consequence of phosphorylation of these substrates could be decreased cell adhesiveness, an important step leading to the establishment of viable metastatic colonies. Immunoblotting with phosphotyrosine monoclonal antibodies has demonstrated an increase in both the degree and number of phosphorylated proteins in our metastatic lesions relative to the primary tumors and normal mucosa (G. E. Gallick, unpublished data).
Tumor progression invariably leads to increasing autonomy and heterogeneity of cell populations (44) . Whether or not increased activity and level of pp6Ocsrc trigger these processes or are a consequence of other events requires further study. Also, the mechanisms by which the observed changes occur remain unclear. Whatever factors are controlling pp60c-src specific activity and level, our data suggest that a progressive elevation in total activity may be a key component in the cascade of molecular events leading to competent metastatic colon cells. Additionally, when metastases from other primary tumors were examined, similar changes in pp6oCsrc were not observed, suggesting that these regulatory changes may be unique to progression of colon tumors (Talamonti et al., manuscript in preparation).
The consistent elevation of pp6Osrc activity and level in colorectal liver metastases suggests possible diagnostic and therapeutic applications for this oncogene product. Identification and characterization of metastatic-specific tyrosine kinase substrates could serve as important diagnostic molecular markers of tumor progression. Finally, the development of tyrosine kinase inhibitors may provide exceptional specificity as a form of molecular antineoplastic therapy.
